Human disease
urinary bladder cancer
Mondo defines it as: “A primary or metastatic malignant neoplasm involving the bladder.”
2 disease groups in OMIA reach this disease, through OMIA's own Mondo link or its OMIM numbers. The page shows the chain. It does not say whether an animal is a model of this disease.
Animal diseases
By natural-model score for this disease, highest first. The score says how complete and how well supported each chain is, by stated rules. How the score works.
| OMIA group | Name | Found by | Species | The chain reached | Score |
|---|---|---|---|---|---|
| 1990 | Cancer, TP53-related | OMIA's OMIM numbers | 5 | Drug |
76.7
|
| 1512 | Transitional cell carcinoma | OMIA's OMIM numbers | 2 | Drug |
62.0
|
Human genes
Each human gene of these disease groups that Open Targets links to this disease.
| Human gene | Score | Evidence |
|---|---|---|
| TP53 | 0.71 | 1,547 |
| KRAS | 0.70 | 153 |
| BRAF | 0.29 | 32 |
| MAP2K1 | 0.07 | 15 |
| NIPAL1 | 0.00 | 1 |
Drugs tested for this disease
Each ChEMBL drug that has been tested for this disease, and the human genes above it acts on, if any. Open Targets gives some drugs, such as most enzyme replacement therapies, no target gene.
| Drug | Acts on | Latest stage for this disease |
|---|---|---|
| Apaziquone | None of these genes | Phase 3 |
| Atezolizumab | None of these genes | Phase 3 |
| Bcg Live | None of these genes | Phase 3 |
| Bcg Vaccine | None of these genes | Phase 3 |
| Bempegaldesleukin | None of these genes | Phase 3 |
| Carboplatin | None of these genes | Phase 3 |
| Cisplatin | None of these genes | Phase 3 |
| Doxorubicin | None of these genes | Phase 3 |
| Durvalumab | None of these genes | Phase 3 |
| Eflornithine | None of these genes | Phase 3 |
| Enfortumab Vedotin | None of these genes | Phase 3 |
| Epirubicin | None of these genes | Phase 3 |
| Erdafitinib | None of these genes | Phase 3 |
| Fluorouracil | None of these genes | Phase 3 |
| Gemcitabine | None of these genes | Phase 3 |
| Infigratinib | None of these genes | Phase 3 |
| Keyhole Limpet Hemocyanin | None of these genes | Phase 3 |
| Methotrexate | None of these genes | Phase 3 |
| Mitomycin | None of these genes | Phase 3 |
| Nivolumab | None of these genes | Phase 3 |
| Oportuzumab Monatox | None of these genes | Phase 3 |
| Sasanlimab | None of these genes | Phase 3 |
| Selenium | None of these genes | Phase 3 |
| Tremelimumab | None of these genes | Phase 3 |
| Valrubicin | None of these genes | Phase 3 |
| Vinblastine | None of these genes | Phase 3 |
| Vitamin E | None of these genes | Phase 3 |
| Lapatinib | None of these genes | Phase 2/3 |
| Tranexamic Acid | None of these genes | Phase 2/3 |
| Amifostine | None of these genes | Phase 2 |
| Avelumab | None of these genes | Phase 2 |
| Bevacizumab | None of these genes | Phase 2 |
| Bicalutamide | None of these genes | Phase 2 |
| Disitamab Vedotin | None of these genes | Phase 2 |
| Docetaxel Anhydrous | None of these genes | Phase 2 |
| Erlotinib | None of these genes | Phase 2 |
| Interferon Alfa-2b | None of these genes | Phase 2 |
| Ipilimumab | None of these genes | Phase 2 |
| Metformin | None of these genes | Phase 2 |
| Oxaliplatin | None of these genes | Phase 2 |
| Paclitaxel | None of these genes | Phase 2 |
| Panitumumab | None of these genes | Phase 2 |
| Pazopanib | None of these genes | Phase 2 |
| Pembrolizumab | None of these genes | Phase 2 |
| Propranolol | None of these genes | Phase 2 |
| Rogaratinib | None of these genes | Phase 2 |
| Simvastatin | None of these genes | Phase 2 |
| Sorafenib | BRAF | Phase 2 |
| Sunitinib | None of these genes | Phase 2 |
| Tipifarnib | None of these genes | Phase 2 |
| Tislelizumab | None of these genes | Phase 2 |
| Ascorbic Acid | None of these genes | Phase 1/2 |
| Belinostat | None of these genes | Phase 1/2 |
| Catumaxomab | None of these genes | Phase 1/2 |
| Eribulin | None of these genes | Phase 1/2 |
| Filgrastim | None of these genes | Phase 1/2 |
| Ifosfamide | None of these genes | Phase 1/2 |
| Inbakicept | None of these genes | Phase 1/2 |
| Intismeran Autogene | None of these genes | Phase 1/2 |
| Nogapendekin Alfa | None of these genes | Phase 1/2 |
| Pemvidutide | None of these genes | Phase 1/2 |
| Porfimer Sodium | None of these genes | Phase 1/2 |
| Tinengotinib | None of these genes | Phase 1/2 |
| Vinflunine | None of these genes | Phase 1/2 |
| Adavosertib | None of these genes | Phase 1 |
| Celecoxib | None of these genes | Phase 1 |
| Cretostimogene Grenadenorepvec | None of these genes | Phase 1 |
| Danvatirsen | None of these genes | Phase 1 |
| Enzalutamide | None of these genes | Phase 1 |
| Fexagratinib | None of these genes | Phase 1 |
| Gebasaxturev | None of these genes | Phase 1 |
| Hyaluronidase | None of these genes | Phase 1 |
| Imiquimod | None of these genes | Phase 1 |
| Lmb-9 | None of these genes | Phase 1 |
| Nanrilkefusp Alfa | None of these genes | Phase 1 |
| Numidargistat | None of these genes | Phase 1 |
| Olaparib | None of these genes | Phase 1 |
| Selumetinib | MAP2K1 | Phase 1 |
| Suramin | None of these genes | Phase 1 |
| Vistusertib | None of these genes | Phase 1 |
| Vofatamab | None of these genes | Phase 1 |
| Vorinostat | None of these genes | Phase 1 |
| Zalifrelimab | None of these genes | Phase 1 |
| Valproic Acid | None of these genes | Early phase 1 |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.